It is the only available pump that conveniently displays a user’s insulin delivery activity and Dexcom G5 Mobile CGM data together on a single device. The t:slim X2 Pump is also the only insulin pump ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps, today announced receipt of CE mark approval for ...

It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...

On the day of the approval, top FDA and CMS officials write in JAMA of the need to share data for better healthcare delivery. The FDA today expanded its approval for Dexcom’s G5 mobile continuous ...

For the first time, the US Food and Drug Administration has approved the use of a continuous glucose monitoring (CGM) system to replace finger-stick testing for determining insulin doses. The decision ...

A new clinical trial to investigate the use of artificial pancreas system is set to begin, bringing in touchscreen insulin pump maker Tandem Diabetes Care; Dexcom, which makes continuous glucose ...

Dexcom Executive Vice President and Chief Commercial Officer RIck Doubleday visited The American Journal of Managed Care® to discuss Medicare reimbursement for the Dexcom G5 and a new partnership with ...

Hybrid closed-loop systems are increasingly gaining recognition as a gold-standard option for diabetes management, and medtech makers are jumping at the opportunity to add their own artificial ...

* Tandem diabetes care inc- ‍t:slim X2 pump with Dexcom G5 mobile CGM integration is approved for ages 6 and older Source text for Eikon: Further company coverage: ...